- Home
- KROS vs REFI Comparison
KROS vs REFI Comparison
Compare KROS & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | REFI |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 241.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KROS | REFI |
|---|---|---|
| Price | $9.94 | $9.77 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.86 | N/A |
| AVG Volume (30 Days) | ★ 198.4K | 138.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | ★ $243,864,000.00 | $48,857,628.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | $2,751.79 | $0.06 |
| P/E Ratio | ★ N/A | $42.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $9.77 |
| 52 Week High | $22.55 | $14.57 |
Technical Indicators
Market Signals| Indicator | KROS | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 27.12 |
| Support Level | $9.74 | N/A |
| Resistance Level | $12.35 | $12.45 |
| Average True Range (ATR) | 0.46 | 0.21 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 7.75 | 5.59 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.